News and Trends 9 May 2023
Recursion boosts drug discovery with Cyclica and Valence acquisitions
Recursion has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica, for $40 million, and Valence, for $47.5 million. Chris Gibson, co-founder and CEO of Salt…